Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Withdraws IPO Registration

NEW YORK (GenomeWeb News) – Fluidigm has decided to the pull the plug on its proposed initial public offering “due to the historic instability in the market,” the firm said today.
 
The South San Francisco-based company had expected to offer 5.3 million shares of common stock at a price of between $14 and $16 per share. It had expected to raise net proceeds of between $70.8 million and $81.9 million from the offering, which was to fund sales and marketing initiatives, R&D activities, and facilities and manufacturing expansion.
 
The IPO was expected to become effective last week, but was put on hold by the current financial crisis in the US.
 
Fluidigm President and CEO Gajus Worthington said in a statement that the company had “received a warm reception from the investment community … [but] pushing ahead with a deal in the current market was not in our best interest.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.